Composition and method for reducing homocysteine caused by drugs containing methyl compounds

• US 20070010492A1
• Filed: 07/07/2006
• Published: 01/11/2007
• Est. Priority Date: 07/11/2005
• Status: Abandoned Application

• Current Assignee: Norman L. Pure
• Original Assignee: Norman L. Pure
• Inventors: Generale, Robert
• Application Number:
  US11/482,557
• Publication Number:
  US 20070010492A1
• Time in Patent Office: Days
• US Class Current: 514/89
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/14 Quaternary ammonium compounds, e.g. edrophonium, choline betaines A61K31/205
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

This invention relates to a method and composition of limiting homocysteine. The composition consists of a problematic drug which specifically contains at least one CH3 methyl group at one or more end(s) of its chemical structure. This problematic drug is combined in an embodiment with one or more antidotal cofactors from among: folic acid, vitamin B6, vitamin B12, trimethylglycine and choline.

Claims

1. A method to limit homocysteine in a person being orally administered a prescription drug or over the counter drug, either of which contains at least one CH3 methyl group at one or more ends of the drugs chemical structure, in a single composition consisting of said drug and the antidote to homocysteine, which consists of at least one or more of the following:

folic acid, vitamin b sub 12, vitamin b sub 6, trimethylglycine and choline.

2. The method of claim 1 wherein an antidote to homocysteine in the form of folic acid is present in the amount of at least 800 mcg per dose of the composition or in such an amount over 800 mcg per dose effective to limit homocysteine.

3. The method of claim 1 wherein an antidote to homocysteine in the form of vitamin b sub 12, preferably methylcobalamin, is present in the amount of at least 1000 mcg per dose of the composition or in such an amount over 1000 mcg per dose effective to limit homocysteine.

4. The method of claim 1 wherein an antidote to homocysteine in the form of vitamin b sub 6, preferably pyridoxyl 5 phosphate, is present in the amount of at least 100 mg per dose of the composition or in such an amount over 100 mg per dose effective to limit homocysteine.

5. The method of claim 1 wherein an antidote to homocysteine in the form of trimethylglycine is present in the amount of at least 500 mg per dose of the composition or in such an amount over 500 mg per dose effective to limit homocysteine.

6. The method of claim 1 wherein an antidote to homocysteine in the form of choline is present in the amount of at least 500 mg per dose of the composition or in such an amount over 500 mg per dose effective to limit homocysteine.